Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00038493|
Recruitment Status : Completed
First Posted : June 3, 2002
Last Update Posted : October 29, 2018
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma Multiforme||Drug: Temozolomide and SCH66336||Phase 2|
Temozolomide at a dose of, 150-200 mg/m2, will be administered orally, after fasting for one hour, once a day for 5 consecutive days (days 1 through 5) every 4 weeks (plus up to 3 days). The starting dose level of 200 mg/m2 will be used for patients who have not previously received any chemotherapy or at 150 mg/m2 for patients who have received previous chemotherapy.
SCH66336 will be given orally, with water, in the morning and in the evening for three weeks (Days 8 - 28) every 28 days (plus up to 3 days) 1 hour before or after morning and evening meals. Patients will take 150 mg in the morning and 150 mg in the evening.
Treatment courses may be repeated every 28 days following the first daily dose of Temozolomide for the previous course.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Evaluation Temozolomide and Farnesyl Transferase Inhibitor (SCH66336) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme|
|Actual Study Start Date :||September 21, 2001|
|Actual Primary Completion Date :||August 1, 2005|
|Actual Study Completion Date :||August 1, 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00038493
|United States, Texas|
|UTMD Anderson Cancer Center|
|Houston, Texas, United States, 77030|